GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » PS Ratio

INAB (IN8bio) PS Ratio : (As of Apr. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is IN8bio PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, IN8bio's share price is $0.1608. IN8bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Hence, IN8bio's PS Ratio for today is .

The historical rank and industry rank for IN8bio's PS Ratio or its related term are showing as below:

INAB's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.1
* Ranked among companies with meaningful PS Ratio only.

IN8bio's Revenue per Sharefor the three months ended in Dec. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00.

Back to Basics: PS Ratio


IN8bio PS Ratio Historical Data

The historical data trend for IN8bio's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio PS Ratio Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PS Ratio
Get a 7-Day Free Trial - - - - -

IN8bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IN8bio's PS Ratio

For the Biotechnology subindustry, IN8bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IN8bio's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's PS Ratio distribution charts can be found below:

* The bar in red indicates where IN8bio's PS Ratio falls into.


;
;

IN8bio PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

IN8bio's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.1608/0
=

IN8bio's Share Price of today is $0.1608.
IN8bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


IN8bio  (NAS:INAB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


IN8bio PS Ratio Related Terms

Thank you for viewing the detailed overview of IN8bio's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IN8bio Business Description

Traded in Other Exchanges
Address
350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Executives
Jeremy R. Graff director C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall officer: Chief Financial Officer C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho director, officer: President, CEO and CFO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l. director, 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc 10 percent owner 10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb officer: EVP and CSO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami officer: Chief Medical Officer C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin officer: Chief Operating Officer IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118